nodes	percent_of_prediction	percent_of_DWPC	metapath
Bumetanide—SLCO1A2—Chlorambucil—testicular cancer	0.264	0.414	CbGbCtD
Bumetanide—SLC22A11—Methotrexate—testicular cancer	0.0708	0.111	CbGbCtD
Bumetanide—SLC22A7—Methotrexate—testicular cancer	0.0674	0.106	CbGbCtD
Bumetanide—CFTR—vas deferens—testicular cancer	0.0651	0.392	CbGeAlD
Bumetanide—PTGS2—Cisplatin—testicular cancer	0.0596	0.0936	CbGbCtD
Bumetanide—PTGS2—Etoposide—testicular cancer	0.0586	0.0919	CbGbCtD
Bumetanide—SLCO1A2—Methotrexate—testicular cancer	0.0473	0.0742	CbGbCtD
Bumetanide—SLC22A8—Methotrexate—testicular cancer	0.0412	0.0646	CbGbCtD
Bumetanide—SLC22A6—Methotrexate—testicular cancer	0.0287	0.045	CbGbCtD
Bumetanide—CFTR—semen—testicular cancer	0.0232	0.14	CbGeAlD
Bumetanide—SLC12A4—embryo—testicular cancer	0.00667	0.0402	CbGeAlD
Bumetanide—CFTR—seminal vesicle—testicular cancer	0.00492	0.0296	CbGeAlD
Bumetanide—SLC12A4—gonad—testicular cancer	0.00453	0.0273	CbGeAlD
Bumetanide—SLC10A1—seminal vesicle—testicular cancer	0.00408	0.0246	CbGeAlD
Bumetanide—CA14—seminal vesicle—testicular cancer	0.00404	0.0243	CbGeAlD
Bumetanide—SLC12A5—testis—testicular cancer	0.00393	0.0237	CbGeAlD
Bumetanide—SLC12A4—female gonad—testicular cancer	0.00368	0.0221	CbGeAlD
Bumetanide—SLC12A4—testis—testicular cancer	0.00326	0.0196	CbGeAlD
Bumetanide—SLC12A2—gonad—testicular cancer	0.00312	0.0188	CbGeAlD
Bumetanide—SLC10A1—gonad—testicular cancer	0.00295	0.0178	CbGeAlD
Bumetanide—CFTR—female gonad—testicular cancer	0.00289	0.0174	CbGeAlD
Bumetanide—CFTR—testis—testicular cancer	0.00256	0.0154	CbGeAlD
Bumetanide—SLC12A2—female gonad—testicular cancer	0.00254	0.0153	CbGeAlD
Bumetanide—Blood uric acid increased—Chlorambucil—testicular cancer	0.00238	0.0134	CcSEcCtD
Bumetanide—SLC12A4—lymph node—testicular cancer	0.00236	0.0142	CbGeAlD
Bumetanide—SLC12A2—testis—testicular cancer	0.00225	0.0136	CbGeAlD
Bumetanide—CA9—testis—testicular cancer	0.00222	0.0133	CbGeAlD
Bumetanide—Serum creatinine increased—Cisplatin—testicular cancer	0.00216	0.0122	CcSEcCtD
Bumetanide—SLC10A1—testis—testicular cancer	0.00213	0.0128	CbGeAlD
Bumetanide—CA5B—gonad—testicular cancer	0.00204	0.0123	CbGeAlD
Bumetanide—Cholestasis—Ifosfamide—testicular cancer	0.00203	0.0114	CcSEcCtD
Bumetanide—CA4—seminal vesicle—testicular cancer	0.00195	0.0117	CbGeAlD
Bumetanide—SLC22A7—testis—testicular cancer	0.0019	0.0114	CbGeAlD
Bumetanide—SLC12A1—testis—testicular cancer	0.00189	0.0114	CbGeAlD
Bumetanide—SLC12A2—lymph node—testicular cancer	0.00163	0.00983	CbGeAlD
Bumetanide—Hearing impaired—Ifosfamide—testicular cancer	0.00162	0.00911	CcSEcCtD
Bumetanide—SLC12A5—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.00159	0.0855	CbGpPWpGaD
Bumetanide—SLC12A4—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.00159	0.0855	CbGpPWpGaD
Bumetanide—Liver injury—Cisplatin—testicular cancer	0.00158	0.00889	CcSEcCtD
Bumetanide—Toxic epidermal necrolysis—Chlorambucil—testicular cancer	0.00153	0.00857	CcSEcCtD
Bumetanide—CA5B—testis—testicular cancer	0.00147	0.00886	CbGeAlD
Bumetanide—Hyperuricaemia—Cisplatin—testicular cancer	0.00144	0.00806	CcSEcCtD
Bumetanide—Hearing impaired—Cisplatin—testicular cancer	0.0014	0.00786	CcSEcCtD
Bumetanide—Azotaemia—Methotrexate—testicular cancer	0.00137	0.0077	CcSEcCtD
Bumetanide—Blood uric acid increased—Cisplatin—testicular cancer	0.00136	0.00761	CcSEcCtD
Bumetanide—SLC12A2—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.00135	0.0727	CbGpPWpGaD
Bumetanide—Hepatocellular injury—Cisplatin—testicular cancer	0.00133	0.00748	CcSEcCtD
Bumetanide—Hyperuricaemia—Etoposide—testicular cancer	0.00131	0.00738	CcSEcCtD
Bumetanide—Stevens-Johnson syndrome—Chlorambucil—testicular cancer	0.00129	0.00727	CcSEcCtD
Bumetanide—Polyuria—Ifosfamide—testicular cancer	0.00128	0.00717	CcSEcCtD
Bumetanide—PTGS2—embryo—testicular cancer	0.00127	0.00765	CbGeAlD
Bumetanide—Blood uric acid increased—Etoposide—testicular cancer	0.00124	0.00698	CcSEcCtD
Bumetanide—PTGS2—seminal vesicle—testicular cancer	0.00119	0.00718	CbGeAlD
Bumetanide—SLCO1A2—testis—testicular cancer	0.00115	0.00691	CbGeAlD
Bumetanide—CA4—female gonad—testicular cancer	0.00114	0.00689	CbGeAlD
Bumetanide—Encephalopathy—Methotrexate—testicular cancer	0.00114	0.00639	CcSEcCtD
Bumetanide—Serum creatinine increased—Epirubicin—testicular cancer	0.00111	0.00624	CcSEcCtD
Bumetanide—Erythema multiforme—Chlorambucil—testicular cancer	0.00111	0.00623	CcSEcCtD
Bumetanide—Toxic epidermal necrolysis—Dactinomycin—testicular cancer	0.0011	0.00619	CcSEcCtD
Bumetanide—Polyuria—Cisplatin—testicular cancer	0.0011	0.00618	CcSEcCtD
Bumetanide—CA5B—lymph node—testicular cancer	0.00107	0.00642	CbGeAlD
Bumetanide—SLC22A11—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.00105	0.0568	CbGpPWpGaD
Bumetanide—Blood creatinine increased—Ifosfamide—testicular cancer	0.00105	0.0059	CcSEcCtD
Bumetanide—Serum creatinine increased—Doxorubicin—testicular cancer	0.00103	0.00578	CcSEcCtD
Bumetanide—Hypokalaemia—Ifosfamide—testicular cancer	0.00102	0.00573	CcSEcCtD
Bumetanide—CA4—testis—testicular cancer	0.00101	0.00611	CbGeAlD
Bumetanide—Toxic epidermal necrolysis—Ifosfamide—testicular cancer	0.00101	0.00567	CcSEcCtD
Bumetanide—Hyperventilation—Epirubicin—testicular cancer	0.000994	0.00558	CcSEcCtD
Bumetanide—Hyponatraemia—Cisplatin—testicular cancer	0.00097	0.00545	CcSEcCtD
Bumetanide—SLC22A7—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.000956	0.0515	CbGpPWpGaD
Bumetanide—Pancreatitis—Ifosfamide—testicular cancer	0.00095	0.00534	CcSEcCtD
Bumetanide—Stevens-Johnson syndrome—Dactinomycin—testicular cancer	0.000935	0.00525	CcSEcCtD
Bumetanide—Hyperventilation—Doxorubicin—testicular cancer	0.000919	0.00516	CcSEcCtD
Bumetanide—Leukopenia—Chlorambucil—testicular cancer	0.000914	0.00513	CcSEcCtD
Bumetanide—Blood creatinine increased—Cisplatin—testicular cancer	0.000905	0.00509	CcSEcCtD
Bumetanide—Dehydration—Cisplatin—testicular cancer	0.000899	0.00505	CcSEcCtD
Bumetanide—Hypokalaemia—Cisplatin—testicular cancer	0.00088	0.00494	CcSEcCtD
Bumetanide—Hyperglycaemia—Ifosfamide—testicular cancer	0.000874	0.00491	CcSEcCtD
Bumetanide—Cramp muscle—Cisplatin—testicular cancer	0.00087	0.00489	CcSEcCtD
Bumetanide—Stevens-Johnson syndrome—Ifosfamide—testicular cancer	0.000857	0.00481	CcSEcCtD
Bumetanide—Renal failure—Ifosfamide—testicular cancer	0.000849	0.00477	CcSEcCtD
Bumetanide—Glycosuria—Epirubicin—testicular cancer	0.000844	0.00474	CcSEcCtD
Bumetanide—Vertigo—Vinblastine—testicular cancer	0.00084	0.00472	CcSEcCtD
Bumetanide—Leukopenia—Vinblastine—testicular cancer	0.000837	0.0047	CcSEcCtD
Bumetanide—Pancreatitis—Cisplatin—testicular cancer	0.000819	0.0046	CcSEcCtD
Bumetanide—Blood disorder—Epirubicin—testicular cancer	0.000819	0.0046	CcSEcCtD
Bumetanide—Thrombocytopenia—Chlorambucil—testicular cancer	0.000816	0.00458	CcSEcCtD
Bumetanide—Liver injury—Epirubicin—testicular cancer	0.000813	0.00456	CcSEcCtD
Bumetanide—SLC12A4—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000806	0.0435	CbGpPWpGaD
Bumetanide—SLC12A5—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000806	0.0435	CbGpPWpGaD
Bumetanide—CFTR—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000806	0.0435	CbGpPWpGaD
Bumetanide—SLC22A8—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.000803	0.0433	CbGpPWpGaD
Bumetanide—SLC12A1—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000802	0.0433	CbGpPWpGaD
Bumetanide—Abdominal discomfort—Cisplatin—testicular cancer	0.000801	0.0045	CcSEcCtD
Bumetanide—Erythema multiforme—Dactinomycin—testicular cancer	0.0008	0.00449	CcSEcCtD
Bumetanide—Toxic epidermal necrolysis—Etoposide—testicular cancer	0.000797	0.00448	CcSEcCtD
Bumetanide—Cramp muscle—Etoposide—testicular cancer	0.000797	0.00448	CcSEcCtD
Bumetanide—Hyperuricaemia—Methotrexate—testicular cancer	0.000788	0.00442	CcSEcCtD
Bumetanide—Glycosuria—Doxorubicin—testicular cancer	0.000781	0.00439	CcSEcCtD
Bumetanide—Blood disorder—Doxorubicin—testicular cancer	0.000757	0.00425	CcSEcCtD
Bumetanide—Liver injury—Doxorubicin—testicular cancer	0.000752	0.00422	CcSEcCtD
Bumetanide—Thrombocytopenia—Vinblastine—testicular cancer	0.000747	0.0042	CcSEcCtD
Bumetanide—Blood uric acid increased—Methotrexate—testicular cancer	0.000744	0.00418	CcSEcCtD
Bumetanide—Hyperuricaemia—Epirubicin—testicular cancer	0.000737	0.00414	CcSEcCtD
Bumetanide—CA4—lymph node—testicular cancer	0.000736	0.00443	CbGeAlD
Bumetanide—PTGS2—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGDS—testicular cancer	0.000736	0.0397	CbGpPWpGaD
Bumetanide—Erythema multiforme—Ifosfamide—testicular cancer	0.000733	0.00412	CcSEcCtD
Bumetanide—Renal failure—Cisplatin—testicular cancer	0.000732	0.00411	CcSEcCtD
Bumetanide—Fatigue—Chlorambucil—testicular cancer	0.000718	0.00403	CcSEcCtD
Bumetanide—Leukopenia—Bleomycin—testicular cancer	0.000707	0.00397	CcSEcCtD
Bumetanide—PTGS2—female gonad—testicular cancer	0.000701	0.00422	CbGeAlD
Bumetanide—Blood uric acid increased—Epirubicin—testicular cancer	0.000696	0.00391	CcSEcCtD
Bumetanide—Musculoskeletal pain—Epirubicin—testicular cancer	0.000692	0.00389	CcSEcCtD
Bumetanide—SLC12A2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000686	0.037	CbGpPWpGaD
Bumetanide—Hepatocellular injury—Epirubicin—testicular cancer	0.000684	0.00384	CcSEcCtD
Bumetanide—Hyperuricaemia—Doxorubicin—testicular cancer	0.000682	0.00383	CcSEcCtD
Bumetanide—Gastrointestinal pain—Chlorambucil—testicular cancer	0.000681	0.00383	CcSEcCtD
Bumetanide—Stevens-Johnson syndrome—Etoposide—testicular cancer	0.000676	0.0038	CcSEcCtD
Bumetanide—Chest pain—Bleomycin—testicular cancer	0.000673	0.00378	CcSEcCtD
Bumetanide—Renal failure—Etoposide—testicular cancer	0.000671	0.00377	CcSEcCtD
Bumetanide—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.000671	0.0361	CbGpPWpGaD
Bumetanide—Urticaria—Chlorambucil—testicular cancer	0.000662	0.00372	CcSEcCtD
Bumetanide—Leukopenia—Dactinomycin—testicular cancer	0.000659	0.0037	CcSEcCtD
Bumetanide—Abdominal pain—Chlorambucil—testicular cancer	0.000659	0.0037	CcSEcCtD
Bumetanide—Gynaecomastia—Methotrexate—testicular cancer	0.000654	0.00367	CcSEcCtD
Bumetanide—Blood uric acid increased—Doxorubicin—testicular cancer	0.000644	0.00362	CcSEcCtD
Bumetanide—Musculoskeletal pain—Doxorubicin—testicular cancer	0.00064	0.0036	CcSEcCtD
Bumetanide—Hepatocellular injury—Doxorubicin—testicular cancer	0.000633	0.00355	CcSEcCtD
Bumetanide—Thrombocytopenia—Bleomycin—testicular cancer	0.000631	0.00355	CcSEcCtD
Bumetanide—Gastrointestinal pain—Vinblastine—testicular cancer	0.000624	0.00351	CcSEcCtD
Bumetanide—Vertigo—Ifosfamide—testicular cancer	0.000607	0.00341	CcSEcCtD
Bumetanide—Leukopenia—Ifosfamide—testicular cancer	0.000604	0.00339	CcSEcCtD
Bumetanide—Polyuria—Methotrexate—testicular cancer	0.000604	0.00339	CcSEcCtD
Bumetanide—Abdominal pain—Vinblastine—testicular cancer	0.000603	0.00339	CcSEcCtD
Bumetanide—Hypotension—Bleomycin—testicular cancer	0.000602	0.00338	CcSEcCtD
Bumetanide—Asthenia—Chlorambucil—testicular cancer	0.000598	0.00336	CcSEcCtD
Bumetanide—Pruritus—Chlorambucil—testicular cancer	0.000589	0.00331	CcSEcCtD
Bumetanide—Thrombocytopenia—Dactinomycin—testicular cancer	0.000589	0.00331	CcSEcCtD
Bumetanide—Erythema multiforme—Etoposide—testicular cancer	0.000579	0.00325	CcSEcCtD
Bumetanide—Chest pain—Ifosfamide—testicular cancer	0.000575	0.00323	CcSEcCtD
Bumetanide—Arthralgia—Ifosfamide—testicular cancer	0.000575	0.00323	CcSEcCtD
Bumetanide—Diarrhoea—Chlorambucil—testicular cancer	0.00057	0.0032	CcSEcCtD
Bumetanide—Muscle spasms—Cisplatin—testicular cancer	0.00056	0.00314	CcSEcCtD
Bumetanide—Asthenia—Vinblastine—testicular cancer	0.000548	0.00308	CcSEcCtD
Bumetanide—Thrombocytopenia—Ifosfamide—testicular cancer	0.000539	0.00303	CcSEcCtD
Bumetanide—Hyperhidrosis—Ifosfamide—testicular cancer	0.000533	0.00299	CcSEcCtD
Bumetanide—Vomiting—Chlorambucil—testicular cancer	0.00053	0.00297	CcSEcCtD
Bumetanide—Diarrhoea—Vinblastine—testicular cancer	0.000522	0.00293	CcSEcCtD
Bumetanide—Leukopenia—Cisplatin—testicular cancer	0.000521	0.00293	CcSEcCtD
Bumetanide—Fatigue—Dactinomycin—testicular cancer	0.000518	0.00291	CcSEcCtD
Bumetanide—Hypotension—Ifosfamide—testicular cancer	0.000515	0.00289	CcSEcCtD
Bumetanide—Muscle spasms—Etoposide—testicular cancer	0.000513	0.00288	CcSEcCtD
Bumetanide—Urticaria—Bleomycin—testicular cancer	0.000512	0.00288	CcSEcCtD
Bumetanide—Dizziness—Vinblastine—testicular cancer	0.000505	0.00284	CcSEcCtD
Bumetanide—Hyponatraemia—Epirubicin—testicular cancer	0.000498	0.0028	CcSEcCtD
Bumetanide—Nausea—Chlorambucil—testicular cancer	0.000495	0.00278	CcSEcCtD
Bumetanide—Gastrointestinal pain—Dactinomycin—testicular cancer	0.000492	0.00276	CcSEcCtD
Bumetanide—Vomiting—Vinblastine—testicular cancer	0.000485	0.00273	CcSEcCtD
Bumetanide—Vertigo—Etoposide—testicular cancer	0.000479	0.00269	CcSEcCtD
Bumetanide—SLC22A11—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000479	0.0258	CbGpPWpGaD
Bumetanide—Headache—Vinblastine—testicular cancer	0.000478	0.00269	CcSEcCtD
Bumetanide—Toxic epidermal necrolysis—Methotrexate—testicular cancer	0.000478	0.00268	CcSEcCtD
Bumetanide—Leukopenia—Etoposide—testicular cancer	0.000477	0.00268	CcSEcCtD
Bumetanide—Abdominal pain—Dactinomycin—testicular cancer	0.000475	0.00267	CcSEcCtD
Bumetanide—Fatigue—Ifosfamide—testicular cancer	0.000475	0.00267	CcSEcCtD
Bumetanide—Thrombocytopenia—Cisplatin—testicular cancer	0.000465	0.00261	CcSEcCtD
Bumetanide—Blood creatinine increased—Epirubicin—testicular cancer	0.000465	0.00261	CcSEcCtD
Bumetanide—Asthenia—Bleomycin—testicular cancer	0.000463	0.0026	CcSEcCtD
Bumetanide—Dehydration—Epirubicin—testicular cancer	0.000462	0.00259	CcSEcCtD
Bumetanide—Hyponatraemia—Doxorubicin—testicular cancer	0.000461	0.00259	CcSEcCtD
Bumetanide—Hyperhidrosis—Cisplatin—testicular cancer	0.000459	0.00258	CcSEcCtD
Bumetanide—Pruritus—Bleomycin—testicular cancer	0.000456	0.00256	CcSEcCtD
Bumetanide—Chest pain—Etoposide—testicular cancer	0.000454	0.00255	CcSEcCtD
Bumetanide—Nausea—Vinblastine—testicular cancer	0.000453	0.00255	CcSEcCtD
Bumetanide—Hypokalaemia—Epirubicin—testicular cancer	0.000452	0.00254	CcSEcCtD
Bumetanide—Gastrointestinal pain—Ifosfamide—testicular cancer	0.000451	0.00253	CcSEcCtD
Bumetanide—PTGS2—lymph node—testicular cancer	0.00045	0.00271	CbGeAlD
Bumetanide—Pancreatitis—Methotrexate—testicular cancer	0.000449	0.00252	CcSEcCtD
Bumetanide—Toxic epidermal necrolysis—Epirubicin—testicular cancer	0.000447	0.00251	CcSEcCtD
Bumetanide—Hypotension—Cisplatin—testicular cancer	0.000444	0.00249	CcSEcCtD
Bumetanide—Abdominal discomfort—Methotrexate—testicular cancer	0.000439	0.00247	CcSEcCtD
Bumetanide—Urticaria—Ifosfamide—testicular cancer	0.000438	0.00246	CcSEcCtD
Bumetanide—Abdominal pain—Ifosfamide—testicular cancer	0.000436	0.00245	CcSEcCtD
Bumetanide—SLC22A7—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000434	0.0234	CbGpPWpGaD
Bumetanide—Asthenia—Dactinomycin—testicular cancer	0.000431	0.00242	CcSEcCtD
Bumetanide—Blood creatinine increased—Doxorubicin—testicular cancer	0.00043	0.00242	CcSEcCtD
Bumetanide—Dehydration—Doxorubicin—testicular cancer	0.000427	0.0024	CcSEcCtD
Bumetanide—Thrombocytopenia—Etoposide—testicular cancer	0.000426	0.00239	CcSEcCtD
Bumetanide—Hyperhidrosis—Etoposide—testicular cancer	0.000421	0.00236	CcSEcCtD
Bumetanide—Pancreatitis—Epirubicin—testicular cancer	0.000421	0.00236	CcSEcCtD
Bumetanide—Hypokalaemia—Doxorubicin—testicular cancer	0.000418	0.00235	CcSEcCtD
Bumetanide—Toxic epidermal necrolysis—Doxorubicin—testicular cancer	0.000414	0.00232	CcSEcCtD
Bumetanide—Diarrhoea—Dactinomycin—testicular cancer	0.000411	0.00231	CcSEcCtD
Bumetanide—Vomiting—Bleomycin—testicular cancer	0.00041	0.0023	CcSEcCtD
Bumetanide—SLC12A1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000408	0.022	CbGpPWpGaD
Bumetanide—Hypotension—Etoposide—testicular cancer	0.000407	0.00228	CcSEcCtD
Bumetanide—Rash—Bleomycin—testicular cancer	0.000407	0.00228	CcSEcCtD
Bumetanide—Dermatitis—Bleomycin—testicular cancer	0.000406	0.00228	CcSEcCtD
Bumetanide—Stevens-Johnson syndrome—Methotrexate—testicular cancer	0.000405	0.00228	CcSEcCtD
Bumetanide—Renal failure—Methotrexate—testicular cancer	0.000402	0.00226	CcSEcCtD
Bumetanide—Asthenia—Ifosfamide—testicular cancer	0.000395	0.00222	CcSEcCtD
Bumetanide—Sweating—Methotrexate—testicular cancer	0.000392	0.0022	CcSEcCtD
Bumetanide—Pruritus—Ifosfamide—testicular cancer	0.00039	0.00219	CcSEcCtD
Bumetanide—Pancreatitis—Doxorubicin—testicular cancer	0.000389	0.00219	CcSEcCtD
Bumetanide—Hyperglycaemia—Epirubicin—testicular cancer	0.000387	0.00217	CcSEcCtD
Bumetanide—Nausea—Bleomycin—testicular cancer	0.000383	0.00215	CcSEcCtD
Bumetanide—Vomiting—Dactinomycin—testicular cancer	0.000382	0.00215	CcSEcCtD
Bumetanide—Stevens-Johnson syndrome—Epirubicin—testicular cancer	0.000379	0.00213	CcSEcCtD
Bumetanide—Rash—Dactinomycin—testicular cancer	0.000379	0.00213	CcSEcCtD
Bumetanide—Diarrhoea—Ifosfamide—testicular cancer	0.000377	0.00212	CcSEcCtD
Bumetanide—Renal failure—Epirubicin—testicular cancer	0.000376	0.00211	CcSEcCtD
Bumetanide—Fatigue—Etoposide—testicular cancer	0.000375	0.00211	CcSEcCtD
Bumetanide—Sweating—Epirubicin—testicular cancer	0.000367	0.00206	CcSEcCtD
Bumetanide—SLC22A8—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000365	0.0197	CbGpPWpGaD
Bumetanide—Dizziness—Ifosfamide—testicular cancer	0.000364	0.00205	CcSEcCtD
Bumetanide—Hyperglycaemia—Doxorubicin—testicular cancer	0.000358	0.00201	CcSEcCtD
Bumetanide—Nausea—Dactinomycin—testicular cancer	0.000357	0.00201	CcSEcCtD
Bumetanide—Gastrointestinal pain—Etoposide—testicular cancer	0.000356	0.002	CcSEcCtD
Bumetanide—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	0.000351	0.00197	CcSEcCtD
Bumetanide—Vomiting—Ifosfamide—testicular cancer	0.00035	0.00197	CcSEcCtD
Bumetanide—Renal failure—Doxorubicin—testicular cancer	0.000348	0.00195	CcSEcCtD
Bumetanide—Rash—Ifosfamide—testicular cancer	0.000347	0.00195	CcSEcCtD
Bumetanide—Dermatitis—Ifosfamide—testicular cancer	0.000347	0.00195	CcSEcCtD
Bumetanide—Erythema multiforme—Methotrexate—testicular cancer	0.000347	0.00195	CcSEcCtD
Bumetanide—Urticaria—Etoposide—testicular cancer	0.000346	0.00194	CcSEcCtD
Bumetanide—Abdominal pain—Etoposide—testicular cancer	0.000344	0.00193	CcSEcCtD
Bumetanide—Asthenia—Cisplatin—testicular cancer	0.000341	0.00191	CcSEcCtD
Bumetanide—Sweating—Doxorubicin—testicular cancer	0.000339	0.00191	CcSEcCtD
Bumetanide—Nausea—Ifosfamide—testicular cancer	0.000327	0.00184	CcSEcCtD
Bumetanide—Diarrhoea—Cisplatin—testicular cancer	0.000325	0.00183	CcSEcCtD
Bumetanide—Erythema multiforme—Epirubicin—testicular cancer	0.000325	0.00182	CcSEcCtD
Bumetanide—SLCO1A2—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000324	0.0175	CbGpPWpGaD
Bumetanide—Asthenia—Etoposide—testicular cancer	0.000312	0.00175	CcSEcCtD
Bumetanide—Pruritus—Etoposide—testicular cancer	0.000308	0.00173	CcSEcCtD
Bumetanide—SLC22A6—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000305	0.0164	CbGpPWpGaD
Bumetanide—Vomiting—Cisplatin—testicular cancer	0.000302	0.0017	CcSEcCtD
Bumetanide—Erythema multiforme—Doxorubicin—testicular cancer	0.0003	0.00169	CcSEcCtD
Bumetanide—Rash—Cisplatin—testicular cancer	0.0003	0.00168	CcSEcCtD
Bumetanide—Dermatitis—Cisplatin—testicular cancer	0.000299	0.00168	CcSEcCtD
Bumetanide—Diarrhoea—Etoposide—testicular cancer	0.000298	0.00167	CcSEcCtD
Bumetanide—Dizziness—Etoposide—testicular cancer	0.000288	0.00162	CcSEcCtD
Bumetanide—Muscle spasms—Epirubicin—testicular cancer	0.000287	0.00161	CcSEcCtD
Bumetanide—Vertigo—Methotrexate—testicular cancer	0.000287	0.00161	CcSEcCtD
Bumetanide—Leukopenia—Methotrexate—testicular cancer	0.000286	0.00161	CcSEcCtD
Bumetanide—PTGS2—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	0.000284	0.0153	CbGpPWpGaD
Bumetanide—Nausea—Cisplatin—testicular cancer	0.000282	0.00158	CcSEcCtD
Bumetanide—Vomiting—Etoposide—testicular cancer	0.000277	0.00155	CcSEcCtD
Bumetanide—Rash—Etoposide—testicular cancer	0.000274	0.00154	CcSEcCtD
Bumetanide—Dermatitis—Etoposide—testicular cancer	0.000274	0.00154	CcSEcCtD
Bumetanide—Headache—Etoposide—testicular cancer	0.000273	0.00153	CcSEcCtD
Bumetanide—Chest pain—Methotrexate—testicular cancer	0.000272	0.00153	CcSEcCtD
Bumetanide—Arthralgia—Methotrexate—testicular cancer	0.000272	0.00153	CcSEcCtD
Bumetanide—Vertigo—Epirubicin—testicular cancer	0.000269	0.00151	CcSEcCtD
Bumetanide—Leukopenia—Epirubicin—testicular cancer	0.000268	0.0015	CcSEcCtD
Bumetanide—Muscle spasms—Doxorubicin—testicular cancer	0.000266	0.00149	CcSEcCtD
Bumetanide—PTGS2—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000266	0.0143	CbGpPWpGaD
Bumetanide—Nausea—Etoposide—testicular cancer	0.000258	0.00145	CcSEcCtD
Bumetanide—Thrombocytopenia—Methotrexate—testicular cancer	0.000255	0.00143	CcSEcCtD
Bumetanide—Chest pain—Epirubicin—testicular cancer	0.000254	0.00143	CcSEcCtD
Bumetanide—Arthralgia—Epirubicin—testicular cancer	0.000254	0.00143	CcSEcCtD
Bumetanide—Hyperhidrosis—Methotrexate—testicular cancer	0.000252	0.00142	CcSEcCtD
Bumetanide—Dry mouth—Epirubicin—testicular cancer	0.000249	0.0014	CcSEcCtD
Bumetanide—Vertigo—Doxorubicin—testicular cancer	0.000248	0.0014	CcSEcCtD
Bumetanide—Leukopenia—Doxorubicin—testicular cancer	0.000248	0.00139	CcSEcCtD
Bumetanide—Hypotension—Methotrexate—testicular cancer	0.000244	0.00137	CcSEcCtD
Bumetanide—SLC22A11—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000243	0.0131	CbGpPWpGaD
Bumetanide—Thrombocytopenia—Epirubicin—testicular cancer	0.000239	0.00134	CcSEcCtD
Bumetanide—Hyperhidrosis—Epirubicin—testicular cancer	0.000236	0.00132	CcSEcCtD
Bumetanide—Arthralgia—Doxorubicin—testicular cancer	0.000235	0.00132	CcSEcCtD
Bumetanide—Chest pain—Doxorubicin—testicular cancer	0.000235	0.00132	CcSEcCtD
Bumetanide—Dry mouth—Doxorubicin—testicular cancer	0.00023	0.00129	CcSEcCtD
Bumetanide—Hypotension—Epirubicin—testicular cancer	0.000228	0.00128	CcSEcCtD
Bumetanide—Fatigue—Methotrexate—testicular cancer	0.000225	0.00126	CcSEcCtD
Bumetanide—Thrombocytopenia—Doxorubicin—testicular cancer	0.000221	0.00124	CcSEcCtD
Bumetanide—SLC22A7—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000221	0.0119	CbGpPWpGaD
Bumetanide—Hyperhidrosis—Doxorubicin—testicular cancer	0.000218	0.00123	CcSEcCtD
Bumetanide—Gastrointestinal pain—Methotrexate—testicular cancer	0.000213	0.0012	CcSEcCtD
Bumetanide—Hypotension—Doxorubicin—testicular cancer	0.000211	0.00118	CcSEcCtD
Bumetanide—Fatigue—Epirubicin—testicular cancer	0.00021	0.00118	CcSEcCtD
Bumetanide—Urticaria—Methotrexate—testicular cancer	0.000207	0.00116	CcSEcCtD
Bumetanide—Abdominal pain—Methotrexate—testicular cancer	0.000206	0.00116	CcSEcCtD
Bumetanide—Gastrointestinal pain—Epirubicin—testicular cancer	0.000199	0.00112	CcSEcCtD
Bumetanide—Fatigue—Doxorubicin—testicular cancer	0.000195	0.00109	CcSEcCtD
Bumetanide—Urticaria—Epirubicin—testicular cancer	0.000194	0.00109	CcSEcCtD
Bumetanide—Abdominal pain—Epirubicin—testicular cancer	0.000193	0.00108	CcSEcCtD
Bumetanide—Asthenia—Methotrexate—testicular cancer	0.000187	0.00105	CcSEcCtD
Bumetanide—SLC22A8—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000186	0.01	CbGpPWpGaD
Bumetanide—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000185	0.00104	CcSEcCtD
Bumetanide—Pruritus—Methotrexate—testicular cancer	0.000184	0.00104	CcSEcCtD
Bumetanide—PTGS2—C-MYB transcription factor network—MAD1L1—testicular cancer	0.000184	0.00991	CbGpPWpGaD
Bumetanide—Urticaria—Doxorubicin—testicular cancer	0.000179	0.00101	CcSEcCtD
Bumetanide—Abdominal pain—Doxorubicin—testicular cancer	0.000178	0.001	CcSEcCtD
Bumetanide—Diarrhoea—Methotrexate—testicular cancer	0.000178	0.001	CcSEcCtD
Bumetanide—Asthenia—Epirubicin—testicular cancer	0.000175	0.000983	CcSEcCtD
Bumetanide—Pruritus—Epirubicin—testicular cancer	0.000173	0.000969	CcSEcCtD
Bumetanide—Dizziness—Methotrexate—testicular cancer	0.000172	0.000968	CcSEcCtD
Bumetanide—Diarrhoea—Epirubicin—testicular cancer	0.000167	0.000937	CcSEcCtD
Bumetanide—Vomiting—Methotrexate—testicular cancer	0.000166	0.000931	CcSEcCtD
Bumetanide—SLCO1A2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000165	0.00888	CbGpPWpGaD
Bumetanide—Rash—Methotrexate—testicular cancer	0.000164	0.000923	CcSEcCtD
Bumetanide—Dermatitis—Methotrexate—testicular cancer	0.000164	0.000922	CcSEcCtD
Bumetanide—Headache—Methotrexate—testicular cancer	0.000163	0.000917	CcSEcCtD
Bumetanide—Asthenia—Doxorubicin—testicular cancer	0.000162	0.00091	CcSEcCtD
Bumetanide—Dizziness—Epirubicin—testicular cancer	0.000161	0.000906	CcSEcCtD
Bumetanide—Pruritus—Doxorubicin—testicular cancer	0.00016	0.000897	CcSEcCtD
Bumetanide—Vomiting—Epirubicin—testicular cancer	0.000155	0.000871	CcSEcCtD
Bumetanide—SLC22A6—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000155	0.00835	CbGpPWpGaD
Bumetanide—Nausea—Methotrexate—testicular cancer	0.000155	0.00087	CcSEcCtD
Bumetanide—Diarrhoea—Doxorubicin—testicular cancer	0.000154	0.000867	CcSEcCtD
Bumetanide—Rash—Epirubicin—testicular cancer	0.000154	0.000864	CcSEcCtD
Bumetanide—Dermatitis—Epirubicin—testicular cancer	0.000154	0.000863	CcSEcCtD
Bumetanide—Headache—Epirubicin—testicular cancer	0.000153	0.000858	CcSEcCtD
Bumetanide—Dizziness—Doxorubicin—testicular cancer	0.000149	0.000838	CcSEcCtD
Bumetanide—Nausea—Epirubicin—testicular cancer	0.000145	0.000814	CcSEcCtD
Bumetanide—Vomiting—Doxorubicin—testicular cancer	0.000144	0.000806	CcSEcCtD
Bumetanide—Rash—Doxorubicin—testicular cancer	0.000142	0.000799	CcSEcCtD
Bumetanide—Dermatitis—Doxorubicin—testicular cancer	0.000142	0.000799	CcSEcCtD
Bumetanide—Headache—Doxorubicin—testicular cancer	0.000141	0.000794	CcSEcCtD
Bumetanide—Nausea—Doxorubicin—testicular cancer	0.000134	0.000753	CcSEcCtD
Bumetanide—CA9—Cellular responses to stress—H2AFZ—testicular cancer	0.000133	0.00717	CbGpPWpGaD
Bumetanide—PTGS2—C-MYB transcription factor network—H2AFZ—testicular cancer	0.000128	0.00691	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	0.000128	0.00689	CbGpPWpGaD
Bumetanide—PTGS2—C-MYB transcription factor network—KITLG—testicular cancer	0.000118	0.00636	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	9.09e-05	0.0049	CbGpPWpGaD
Bumetanide—CA14—Metabolism—HPGDS—testicular cancer	8.08e-05	0.00435	CbGpPWpGaD
Bumetanide—PTGS2—C-MYB transcription factor network—KIT—testicular cancer	8.05e-05	0.00434	CbGpPWpGaD
Bumetanide—CA5A—Metabolism—HPGDS—testicular cancer	7.87e-05	0.00424	CbGpPWpGaD
Bumetanide—CA7—Metabolism—HPGDS—testicular cancer	7.35e-05	0.00396	CbGpPWpGaD
Bumetanide—CA5B—Metabolism—HPGDS—testicular cancer	7.35e-05	0.00396	CbGpPWpGaD
Bumetanide—CA12—Metabolism—HPGDS—testicular cancer	6.81e-05	0.00367	CbGpPWpGaD
Bumetanide—PTGS2—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	6.61e-05	0.00356	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	6.29e-05	0.00339	CbGpPWpGaD
Bumetanide—CA14—Metabolism—STK11—testicular cancer	5.87e-05	0.00316	CbGpPWpGaD
Bumetanide—CA5A—Metabolism—STK11—testicular cancer	5.72e-05	0.00308	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—HPGDS—testicular cancer	5.69e-05	0.00307	CbGpPWpGaD
Bumetanide—CA4—Metabolism—HPGDS—testicular cancer	5.43e-05	0.00293	CbGpPWpGaD
Bumetanide—CA5B—Metabolism—STK11—testicular cancer	5.34e-05	0.00288	CbGpPWpGaD
Bumetanide—CA7—Metabolism—STK11—testicular cancer	5.34e-05	0.00288	CbGpPWpGaD
Bumetanide—CA12—Metabolism—STK11—testicular cancer	4.95e-05	0.00267	CbGpPWpGaD
Bumetanide—CA9—Metabolism—HPGDS—testicular cancer	4.39e-05	0.00237	CbGpPWpGaD
Bumetanide—SLC10A1—Metabolism—STK11—testicular cancer	4.14e-05	0.00223	CbGpPWpGaD
Bumetanide—CA4—Metabolism—STK11—testicular cancer	3.94e-05	0.00213	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	3.8e-05	0.00205	CbGpPWpGaD
Bumetanide—CA9—Metabolism—STK11—testicular cancer	3.19e-05	0.00172	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—HPGDS—testicular cancer	2.8e-05	0.00151	CbGpPWpGaD
Bumetanide—SLCO1A2—Metabolism—STK11—testicular cancer	2.03e-05	0.0011	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—HPGDS—testicular cancer	1.69e-05	0.000912	CbGpPWpGaD
Bumetanide—PTGS2—Disease—H2AFZ—testicular cancer	1.48e-05	0.000796	CbGpPWpGaD
Bumetanide—PTGS2—Disease—KITLG—testicular cancer	1.36e-05	0.000732	CbGpPWpGaD
Bumetanide—PTGS2—Metabolism—STK11—testicular cancer	1.23e-05	0.000662	CbGpPWpGaD
Bumetanide—PTGS2—Disease—FGFR3—testicular cancer	1.01e-05	0.000544	CbGpPWpGaD
Bumetanide—PTGS2—Disease—KIT—testicular cancer	9.26e-06	0.000499	CbGpPWpGaD
